|

ACADIA PHARMACEUTICALS INC (ACAD)

US0042251084 - Common Stock

20.98  -0.81 (-3.72%)

After market: 20.98 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
441.8M
30.29%		484.1M
9.57%		517.2M
6.84%		734.23M
41.96%
EBITDA
YoY % growth
-283.66M
-16.38%		-167.05M
41.11%		-221.57M
-32.64%		-79.559M
64.09%		N/AN/AN/A
EBIT
YoY % growth
-286.6M
-16.27%		-170.4M
40.54%		-223.6M
-31.22%		-85.61M
61.71%
Operating Margin
-64.87%-35.20%-43.23%-11.66%
EPS
YoY % growth
-1.80
-12.50%		-1.05
41.67%		-0.97
7.62%		-0.35
64.42%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		0.31
220.29%
Revenue
Q2Q % growth		228.87M
67.67%
EBITDA
Q2Q % growth		51.923MN/AN/AN/AN/A
EBIT
Q2Q % growth		47.998M
204.12%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 -0.40
-135.29%		-0.430.037.97%
Q2 2023
Q2Q % growth		 0.01
104.76%		-0.080.09111.87%
Q1 2023
Q2Q % growth		 -0.27
18.18%		-0.22-0.05-23.29%
Q4 2022
Q2Q % growth		 -0.26
3.70%		-0.25-0.01-4.94%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth		 211.7M
61.97%		193.28M18.42M9.53%
Q2 2023
Q2Q % growth		 165.2M
22.73%		160.96M4.24M2.63%
Q1 2023
Q2Q % growth		 118.5M
2.60%		122.69M-4.19M-3.42%
Q4 2022
Q2Q % growth		 136.5M
4.36%		136.75M-250K-0.18%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS5.75% 34.4% 21.87% 19.57%
Revenue2.32% 8.01% 5.48% 6.04%